Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritobegron (KUC 7483) Effect on QT/QTc Interval in Healthy Volunteers
NCT02256735Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of ritobegron in overactive bladder (OAB), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in mean time-matched QTcI at 2 hours. Started Aug 2005; status: completed.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02256735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256735.